QUOIN PHARMACEUTICALS
Quoin Pharmaceuticals is into developing products which address major unmet medical needs including the opioid epidemic and the military veteran suicide rate and chronic rare skin diseases such as Netherton syndrome and Dystrophic Epidermolysis Bullosa (DEB).
QUOIN PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2016-12-01
Address:
Ashburn, Virginia, United States
Country:
United States
Website Url:
http://www.quoinpharma.com
Status:
Active
Contact:
972 58-448-8821
Email Addresses:
[email protected]
Total Funding:
193.54 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Aclipse Therapeutics
Aclipse Therapeutics focuses on developing differentiated drugs to address diseases with unmet medical needs.
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Current Employees Featured
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-04 | Quoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial Officer |
Official Site Inspections
http://www.quoinpharma.com Semrush global rank: 2 M Semrush visits lastest month: 10.63 K
- Host name: 156.31.68.34.bc.googleusercontent.com
- IP address: 34.68.31.156
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Quoin Pharmaceuticals"
Company | Quoin Pharmaceuticals
Formerly, he was President at Boulder Cove and Executive VP of Corporate and Product Development at Medicis Pharmaceutical. He also served as the Chief Business Officer of โฆSee details»
Quoin Pharmaceuticals - Crunchbase Company Profile โฆ
Contact Email [email protected] Phone Number 972 58-448-8821 Quoin Pharmaceuticals is into developing products which address major unmet โฆSee details»
Company Overview | Quoin Pharmaceuticals, Inc.
The Investor Relations website contains information about Quoin Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Quoin Pharmaceuticals Company Overview, Contact Details
Mar 5, 2024 To learn more about Quoin Pharmaceuticals please visit our website: www.quoinpharma.com. Sign up for free to view info. Email Format Employee directory . โฆSee details»
Quoin Pharmaceuticals - LinkedIn
Quoin Pharmaceuticals | 518 followers on LinkedIn. Rare Diseases are only rare if you don't live with one. | Founded in 2018, Quoin is an emerging specialty pharmaceutical company focused โฆSee details»
Quoin Pharmaceuticals Provides Corporate Update and โฆ
For more information, visit: www.quoinpharma.com or LinkedIn for updates. Cautionary Note Regarding Forward Looking Statements The Company cautions that statements in this press โฆSee details»
Quoin Pharmaceuticals
4 days ago Quoin Pharmaceuticals was established in 1998 with the aim of providing high-quality pharmaceutical products for customers in a variety of therapeutic areas.See details»
Quoin Pharmaceuticals Announces Further International Expansion โฆ
Oct 22, 2024 A Principal Investigator (PI) for the UK studies has been appointed and a Clinical Research Organization has been engaged. ... For more information, visit: โฆSee details»
News Release - investors.quoinpharma.com
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the โCompanyโ or โQuoinโ), a clinical stage specialty pharmaceutical company โฆSee details»
Contact - Quoin Pharmaceuticals
Corporate Office. 42127 Pleasant Forest Court Ashburn , VA, 20148-7349 (703) 980-4182 . Quoin Pharmaceuticals is an emerging specialty pharmaceutical company dedicated to supporting โฆSee details»
Quoin Pharmaceuticals Announces FDA Clearance of Clinical โฆ
[email protected]. Investor Relations PCG Advisory Stephanie Prince [email protected] (646) 863-6341. Subscribe. Sign up for alerts to stay up to date on โฆSee details»
Michael Sember | Quoin Pharmaceuticals
Dec 19, 2024 Mr. Sember has served as a director of Quoin Inc. since May 2021 and as a director of Quoin Ltd. since October 28, 2021. In his 40-year career, Mr. Sember has been โฆSee details»
Quoin Pharmaceuticals Ltd. (Quoin Pharmaceuticals Ltd.) - ่ฏ็ฉ็ฎก โฆ
Principal Investigator has Been Appointed and a Clinical Research Organization Has Been Engaged Additional Sites in other Western European Countries are being Finalized โฆSee details»
News Release - investors.quoinpharma.com
Jan 6, 2025 [email protected]. Investor Relations PCG Advisory Jeff Ramson [email protected] (646) 863-6341. Subscribe. Sign up for alerts to stay up to date on โฆSee details»
Quoin Pharmaceuticals Announces Further International Expansion โฆ
Oct 22, 2024 Quoin CEO, Dr. Michael Myers, said, โWe are very pleased to announce yet another exciting development for our ongoing clinical studies. This further international โฆSee details»
Joseph Cooper | Quoin Pharmaceuticals
Nov 5, 2024 Mr. Cooper has served as a director of Quoin Inc. since May 2021. With 30 years of pharmaceutical industry experience, Mr. Cooper has held roles in operational, corporate โฆSee details»
Quoin Pharmaceuticals Announces Further International
Oct 22, 2024 A Principal Investigator (PI) for the UK studies has been appointed and a Clinical Research Organization has been engaged. ... For more information, visit: โฆSee details»
Pipeline - Quoin Pharmaceuticals
Jan 6, 2025 NORD National Organization for Rare Disorders. NORD is leading the fight to improve the lives of patients with rare diseases. Phone: 202-588-5700. Website: โฆSee details»
Quoin Pharmaceuticals to Report Third Quarter 2022 Financial โฆ
ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the โCompanyโ or โQuoinโ), a clinical stage, specialty pharmaceutical company โฆSee details»
Gordon Dunn - Quoin Pharmaceuticals
Dec 20, 2024 Mr. Dunn joined Quoin Pharmaceuticals in November of 2021. He brings over 30 years of finance experience and has served as CFO of both private and publicly traded โฆSee details»